Eli Lilly Publishes P-IIa Study Results of Peresolimab for the Treatment of Rheumatoid Arthritis in the NEJM
Shots:
- The P-IIa study evaluating peresolimab vs PBO in 98 adult patients who had an inadequate response to prior conventional, biological, or synthetic DMARDs
- The trial met its 1EPs for efficacy & had similar rates of AEs b/w both arms, the change from baseline in DAS28-CRP was greater in the 700mg peresolimab vs PBO @12wk. The results from the secondary outcomes favored a 700mg dose for the ACR20 response, improvements from baseline of 20%, 50%, and 70% or more, respectively in the no. of tender, swollen joints and in 3 of 5 important domains @12wk.
- Improvements in CDAI while low disease activity was maintained through 24wk. in patients achieved CDAI low disease activity @14wk., AEs were similar in both groups with no reports of malignancy
Ref: PRNewswire | Image: Eli Lilly
Related News:- Eli Lilly Reports P-III Study (TRAILBLAZER-ALZ 2) Results of Donanemab for the Treatment of Early Alzheimer's Disease
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
